Generic Name and Formulations:
Metipranolol HCl 0.3%; oph soln; contains benzalkonium chloride.
Valeant Pharmaceuticals, Inc
Indications for OPTIPRANOLOL:
1 drop twice daily.
History of, or active, bronchial asthma. Severe COPD. Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure.
Not for use as sole agent in angle-closure glaucoma. History of cardiac failure. Discontinue at first sign of cardiac failure. Cerebrovascular insufficiency. Withdraw gradually before elective surgery. Diabetes. Hyperthyroidism. Myasthenia gravis. History of anaphylaxis. Pregnancy (Cat.C). Nursing mothers.
May potentiate systemic β-blockers, reserpine. Avoid concomitant calcium channel blockers in impaired cardiac function. Caution with adrenergic psychotropics.
Local discomfort. Rarely: conjunctivitis, eyelid dermatitis, blepharitis, blurred vision, tearing, browache, abnormal vision, photophobia, edema. Systemic absorption: bronchospasm, bradycardia, cardiac failure, depression, other β-blocker effects.
Renal and Urology News Articles
- CROWNWeb Reporting Gets Up to Speed With Implementation of Dashboard
- Prostate Cancer Gene Testing Guidelines Issued
- Radical Nephrectomy Linked With Worse Kidney Function, Survival
- Acute Kidney Injury Increases Risk for Hypoglycemia in Diabetes Pts
- USPSTF Questions Nontraditional CVD Risk Factors for Assessment
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)